Number To Know…12.6
Executive Summary
Patients treated with Medtronic's CoreValve Evolut R system for transcatheter aortic valve replacement demonstrated a 12.6% all-cause mortality and disabling stroke rate at two years. This data from the SURVAVI trial convinced the FDA to expand the indication for the device to intermediate risk patients.